Eagle Pharmaceuticals, Inc. (EGRX)

NASDAQ: EGRX · IEX Real-Time Price · USD
33.96
-1.95 (-5.43%)
Dec 5, 2022 4:00 PM EST - Market closed
-5.43%
Market Cap 473.06M
Revenue (ttm) 298.23M
Net Income (ttm) 21.28M
Shares Out 13.17M
EPS (ttm) 1.63
PE Ratio 20.83
Forward PE 11.34
Dividend n/a
Ex-Dividend Date n/a
Volume 148,594
Open 35.82
Previous Close 35.91
Day's Range 33.48 - 35.91
52-Week Range 24.35 - 56.43
Beta 0.80
Analysts Buy
Price Target 39.78 (+17.1%)
Earnings Date Nov 7, 2022

About EGRX

Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma. Its product candidates also include EP-4104, a dantrolene sodium to treat organophosphate exposure; PEMFEXY, a ready-to-use/dilute liquid form of pemetrexed for non-... [Read more]

Industry Biotechnology
IPO Date Feb 12, 2014
CEO Scott Tarriff
Employees 114
Stock Exchange NASDAQ
Ticker Symbol EGRX
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 9 analysts, the average rating for EGRX stock is "Buy." The 12-month stock price forecast is 39.78, which is an increase of 17.14% from the latest price.

Price Target
$39.78
(17.14% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Eagle Pharmaceuticals' Investor Day to Focus on Acute Care Products and Pipeline Programs; Tuesday, December 6, 2022,...

-- Featured speakers and KOLs include: Scott Tarriff, Herm Cukier, Dr. Richard Dutton, Dr. Prem Fort, Dr. TJ Gan, Dr. Andre Kalil, Dr. Joseph Pergolizzi and Dr. Eugene Vortsman -- -- Topics include the ...

4 days ago - GlobeNewsWire

Eagle Pharmaceuticals' Investor Day to Feature World-Renowned KOLs on Tuesday, December 6, 2022, at the Lotte New Yor...

-- Featured speakers and KOLs include: Scott Tarriff, Herm Cukier, Dr. Richard Dutton, Dr. Prem Fort, Dr. TJ Gan, Dr. Andre Kalil, Dr. Joseph Pergolizzi and Dr. Eugene Vortsman -- -- Topics include the ...

2 weeks ago - GlobeNewsWire

Eagle Pharmaceuticals Announces FDA Acceptance of Investigational New Drug Application for CAL02, a Novel First-in-Cl...

-- Expect to begin a Phase 2 study in approximately 276 patients with severe community-acquired pneumonia at approximately 120 sites worldwide -- -- Patient enrollment expected to commence as early as t...

3 weeks ago - GlobeNewsWire

Correcting & Replacing: Eagle Pharmaceuticals Reports Third Quarter 2022 Results

WOODCLIFF LAKE, N.J., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. is re-issuing in its entirety its earnings press release for the third quarter ended September 30, 2022, originally is...

3 weeks ago - GlobeNewsWire

Eagle Pharmaceuticals (EGRX) Q3 Earnings and Revenues Beat Estimates

Eagle Pharmaceuticals (EGRX) delivered earnings and revenue surprises of 33.33% and 11.01%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

4 weeks ago - Zacks Investment Research

Eagle Pharmaceuticals Reports Third Quarter 2022 Results

WOODCLIFF LAKE, N.J., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced financial results for the three and nine months ended Septem...

4 weeks ago - GlobeNewsWire

Is Eagle Pharmaceuticals (EGRX) Stock Undervalued Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest v...

1 month ago - Zacks Investment Research

Eagle Pharmaceuticals to Host Third Quarter 2022 Financial Results on November 7, 2022

WOODCLIFF LAKE, N.J., Oct. 31, 2022 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (“Eagle” or the “Company”) (Nasdaq: EGRX) today announced that the Company will release its 2022 third quarter financi...

1 month ago - GlobeNewsWire

SAVE THE DATE: Eagle Pharmaceuticals to Host Investor Day on Tuesday, December 6, 2022, at the Lotte New York Palace ...

WOODCLIFF LAKE, N.J., Oct. 19, 2022 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that the Company will host an Investor Day on Tuesday, Decem...

1 month ago - GlobeNewsWire

Eagle Pharmaceuticals Announces Submission of Investigational New Drug Application to U.S. Food and Drug Administrati...

-- Company plans to commence an adequately powered Phase 2 study with approximately 276 patients with severe community-acquired pneumonia at 120 sites worldwide with patient enrollment expected as early...

1 month ago - GlobeNewsWire

Eagle Pharmaceuticals and Enalare Therapeutics Announce FDA Orphan Drug Designation for ENA-001 for the Treatment of ...

-- ENA-001, with a novel mechanism of action as an agnostic respiratory stimulant, has previously been granted Rare Pediatric Disease Designation for the treatment of Apnea of Prematurity by the FDA wit...

2 months ago - GlobeNewsWire

Eagle Pharmaceuticals and Enalare Therapeutics Announce Additional Award Worth Up to $50 Million from BARDA to Advanc...

-- ENA-001, a new chemical entity with a unique mechanism of action, is being developed as an agnostic respiratory stimulant for use in multiple patient populations experiencing acute respiratory depres...

2 months ago - GlobeNewsWire

New Strong Sell Stocks for September 26th

EGRX, ACCO and ATUS have been added to the Zacks Rank #5 (Strong Sell) List on September 26, 2022.

Other symbols: ACCOATUS
2 months ago - Zacks Investment Research

New Strong Sell Stocks for September 9th

EGRX, TWTR and PLAY have been added to the Zacks Rank #5 (Strong Sell) List on September 9, 2022.

Other symbols: PLAYTWTR
2 months ago - Zacks Investment Research

New Strong Sell Stocks for September 1st

CCCS, BJRI and EGRX have been added to the Zacks Rank #5 (Strong Sell) List on September 1, 2022.

Other symbols: BJRICCCS
3 months ago - Zacks Investment Research

Eagle Pharmaceuticals to Present at the Morgan Stanley 20th Annual Global Healthcare Conference

WOODCLIFF LAKE, N.J., Aug. 30, 2022 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that Scott Tarriff, President and Chief Executive Officer, a...

3 months ago - GlobeNewsWire

Federal Circuit Rules in Favor of Eagle Pharmaceuticals in Vasopressin Litigation

WOODCLIFF LAKE, N.J., Aug. 18, 2022 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that the U.S. Court of Appeals for the Federal Circuit affir...

3 months ago - GlobeNewsWire

Eagle Pharmaceuticals (EGRX) Q2 Earnings and Revenues Lag Estimates

Eagle Pharmaceuticals (EGRX) delivered earnings and revenue surprises of -50.16% and 31.44%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

3 months ago - Zacks Investment Research

Eagle Pharmaceuticals Reports Second Quarter 2022 Results

•   Q2 2022 net loss was $(0.74) per basic and diluted share and adjusted non-GAAP net income was $1.58 per basic and $1.56 per diluted share

3 months ago - GlobeNewsWire

Eagle Pharmaceuticals Takes Equity Stake in, with Option to Acquire, Enalare Therapeutics to Advance Global Developme...

-- ENA-001 is currently in development for: post-operative respiratory depression, community drug overdose, and Apnea of Prematurity -- -- Approval for post-operative respiratory depression expected in ...

3 months ago - GlobeNewsWire

Eagle Pharmaceuticals Appoints Debra M. Hussain as SVP, Head of Commercial

WOODCLIFF LAKE, N.J., July 18, 2022 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced the appointment of Debra M. Hussain as Senior Vice President...

4 months ago - GlobeNewsWire

Eagle Pharmaceuticals Completes Acquisition of Acacia Pharma Group plc, Expanding Acute Care Footprint

WOODCLIFF LAKE, N.J., June 09, 2022 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced it has completed the acquisition of the entire issued share ...

5 months ago - GlobeNewsWire

Press the Buy Button on These 5 High Earnings Yield Picks Now

One could invest in high earnings yield stocks like Eagle Pharmaceuticals (EGRX), Cabot (CBT), Meritage Homes (MTH), Griffon (GFF) and APA Corp (APA) to fetch handsome long-term rewards.

Other symbols: APACBTGFFMTH
6 months ago - Zacks Investment Research

Eagle Pharmaceuticals Announces Submission of New Drug Application to U.S. Food and Drug Administration for Landiolol...

-- Submission seeks approval for landiolol for the short-term reduction of ventricular rate in patients with supraventricular tachycardia, including atrial fibrillation and atrial flutter -- -- Expected...

6 months ago - GlobeNewsWire

Eagle Pharmaceuticals to Present at the William Blair 42nd Annual Growth Stock Conference

WOODCLIFF LAKE, N.J., May 26, 2022 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle”) today announced that Scott Tarriff, President and Chief Executive Officer, and Brian Cahill, C...

6 months ago - GlobeNewsWire